Drug Profile
Lepirudin
Alternative Names: HBW 023; HEW 023; RefludanLatest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator CSL Behring
- Class Antithrombotics; Hirudins; Recombinant proteins
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Heparin-induced thrombocytopenia and thrombosis syndrome
- Discontinued Deep vein thrombosis; Disseminated intravascular coagulation; Myocardial infarction; Unstable angina pectoris
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
- 08 Mar 2008 Pharmion Corporation has been acquired and merged into Celgene Corporation